Manufacturers announce positive data for Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo, a reversal agent for the Factor Xa inhibitors rivaroxaban or apixaban

The data demonstrated it was associated with a lower rate of in-hospital and 30-day mortality in patients with life-threatening Factor Xa inhibitor-related bleeds vs 4-factor prothrombin complex concentrate. This included lower mortality across multiple bleed types.


Biospace Inc.